Bhramar Mukherjee appointed associate director for population science at University of Michigan Comprehensive Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

BHRAMAR MUKHERJEE was appointed associate director for population science research at The University of Michigan Comprehensive Cancer Center, effective Jan. 15, 2016.

Mukherjee is the John D. Kalbfleisch Collegiate professor of biostatistics and a professor of epidemiology at the U-M School of Public Health. She also serves as the associate chair for biostatistics.

In her new role, she will oversee the center’s research on screening, detection and prevention, as well as research on outcomes, disparities and new models of cancer care delivery.

Mukherjee joined the University of Michigan faculty in 2006. She has received the U-M School of Public Health’s Excellence in Teaching Award and was the recipient this year of the University of Michigan’s Faculty Recognition Award. She is the founding director of a cross-disciplinary summer institute at the School of Public Health to train undergraduates at the intersection of big data and human health. She is also an elected fellow of the American Statistical Association.

Her cancer research has focused on how the interaction between genes and the environment impacts cancer risk. She has studied the roles of diet, physical activity and lifestyle factors, and their interplay with the genetic architecture of an individual.

The associate director for population science position was last held by Stephen Gruber, who is now the director of the University of Southern California Norris Comprehensive Cancer Center.

Table of Contents

YOU MAY BE INTERESTED IN

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login